Skadden Guides Endo In $8B Deal For Generics Co. Par Pharma
Endo International PLC, led by Skadden Arps Slate Meagher & Flom LLP, inked an $8.05 billion deal for TPG Capital Management-backed Par Pharmaceuticals Holdings Inc. on Monday, whisking the generic-drug maker...To view the full article, register now.
Already a subscriber? Click here to view full article